Early post-discharge mortality in CAP: frequency, risk factors and a prediction tool.


Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 30 11 2021
accepted: 31 01 2022
pubmed: 10 2 2022
medline: 23 3 2022
entrez: 9 2 2022
Statut: ppublish

Résumé

There are few data on mortality after discharge with community-acquired pneumonia (CAP). Therefore, we evaluated risk factors for 30-day post-discharge mortality after CAP. We included all patients of the prospective multi-national CAPNETZ study between 2002 and 2018 with (1) hospitalized CAP, (2) survival until discharge, and (3) complete follow-up data. The study endpoint was death within 30 days after discharge. We evaluated risk factors including demographics, comorbidities, admission CAP severity, and laboratory values and treatment-related factors in uni- and multivariable analyses. A total of 126 (1.6%) of 7882 included patients died until day 30 after discharge, corresponding to 26% of all 476 deaths. After multivariable analysis, we identified 10 independent risk factors: higher age, lower BMI, presence of diabetes mellitus, chronic renal or chronic neurological disease (other than cerebrovascular diseases), low body temperature or higher thrombocytes on admission, extended length of hospitalization, oxygen therapy during hospitalization, and post-obstructive pneumonia. By addition these factors, we calculated a risk score with an AUC of 0.831 (95%CI 0.822-0.839, p < 0.001) for prediction of post-discharge mortality. Early post-discharge deaths account for ¼ of all CAP-associated deaths and are associated with patient- and CAP-severity-related risk factors. Additional studies are necessary to replicate our findings in independent cohorts. Study registration: NCT02139163.

Identifiants

pubmed: 35137301
doi: 10.1007/s10096-022-04416-5
pii: 10.1007/s10096-022-04416-5
pmc: PMC8934328
doi:

Banques de données

ClinicalTrials.gov
['NCT02139163']

Types de publication

Clinical Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

621-630

Investigateurs

M Dreher (M)
C Cornelissen (C)
W Knüppel (W)
D Stolz (D)
N Suttorp (N)
P Creutz (P)
M Witzenrath (M)
A Mikolajewska (A)
A le Claire (A)
M Benzke (M)
T Bauer (T)
D Krieger (D)
M Prediger (M)
S Schmager (S)
M Kolditz (M)
B Schulte-Hubbert (B)
S Langner (S)
G Rohde (G)
O Degen (O)
A Hüfner (A)
C Hoffmann (C)
T Welte (T)
J Freise (J)
G Barten-Neiner (G)
M Nawrocki (M)
I Fuge (I)
J Freise (J)
J Naim (J)
W Kröner (W)
T Illig (T)
N Klopp (N)
C Kroegel (C)
A Moeser (A)
M Pletz (M)
B Schleenvoigt (B)
C Bahrs (C)
D Drömann (D)
P Parschke (P)
K Franzen (K)
J Rupp (J)
N Käding (N)
M Wouters (M)
K Walraven (K)
D Braeken (D)
C Spinner (C)
H Buschmann (H)
A Zaruchas (A)
T Schaberg (T)
I Hering (I)
W Albrich (W)
F Waldeck (F)
F Rassouli (F)
S Baldesberger (S)
M Panning (M)
M Wallner (M)

Informations de copyright

© 2022. The Author(s).

Références

Thorax. 2009 Jun;64(6):496-501
pubmed: 19237392
PLoS One. 2016 Feb 05;11(2):e0148741
pubmed: 26849359
Respirology. 2017 Jul;22(5):1000-1006
pubmed: 28221010
Clin Infect Dis. 2016 Apr 15;62(8):957-61
pubmed: 26908806
Chest. 2012 Aug;142(2):476-481
pubmed: 22383662
J Hosp Med. 2011 Mar;6(3):142-50
pubmed: 21387551
Thorax. 2003 May;58(5):377-82
pubmed: 12728155
JAMA Netw Open. 2020 Sep 1;3(9):e2012979
pubmed: 32886119
J Am Coll Cardiol. 2014 Nov 4;64(18):1917-25
pubmed: 25444147
Clin Infect Dis. 2008 Feb 15;46(4):550-6
pubmed: 18194099
BMJ Open. 2018 Mar 30;8(3):e020243
pubmed: 29602852
Infection. 2004 Aug;32(4):234-8
pubmed: 15293080
JAMA. 2018 Dec 25;320(24):2542-2552
pubmed: 30575880
Clin Microbiol Infect. 2011 May;17(5):763-8
pubmed: 20807226
BMJ Open Respir Res. 2021 Mar;8(1):
pubmed: 33771814
Pneumologie. 2021 Sep;75(9):665-729
pubmed: 34198346
Chest. 2013 Mar;143(3):767-775
pubmed: 23187959
Eur Respir J. 2013 Sep;42(3):742-9
pubmed: 23143544
N Engl J Med. 2019 Jan 10;380(2):171-176
pubmed: 30625066
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Respir Med. 2016 Dec;121:32-38
pubmed: 27888989
Semin Respir Crit Care Med. 2016 Dec;37(6):886-896
pubmed: 27960212
Infect Dis Ther. 2018 Mar;7(1):29-38
pubmed: 29392577
Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1103-1111
pubmed: 29600325
Clin Microbiol Infect. 2021 Sep;27(9):1345.e1-1345.e6
pubmed: 33049414

Auteurs

Verena Glöckner (V)

Division of Pulmonology, Medical Department I, University Hospital Carl Gustav Carus of TU Dresden, Fetscherstr. 74, Dresden, 01307, Germany.

Mathias W Pletz (MW)

Institute of Infectious Diseases and Infection Control, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.
CAPNETZ STIFTUNG, Hannover, Germany.

Gernot Rohde (G)

Medical Department I, Department of Respiratory Medicine, Goethe University Hospital, Frankfurt/Main, Germany.
CAPNETZ STIFTUNG, Hannover, Germany.
German Center for Lung Research (DZL), Giessen, Germany.

Jan Rupp (J)

Department of Infectious Diseases and Microbiology, University Hospital Schleswig-Holstein, Lübeck, Germany.
German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel, Giessen, Germany.
CAPNETZ STIFTUNG, Hannover, Germany.

Martin Witzenrath (M)

Department of Infectious Diseases and Pulmonary Medicine, and Division of Pulmonary Inflammation, Charité - Universitätsmedizin Berlin, Berlin, Germany.
CAPNETZ STIFTUNG, Hannover, Germany.
German Center for Lung Research (DZL), Giessen, Germany.

Grit Barten-Neiner (G)

Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Munich, Germany.
CAPNETZ STIFTUNG, Hannover, Germany.

Martin Kolditz (M)

Division of Pulmonology, Medical Department I, University Hospital Carl Gustav Carus of TU Dresden, Fetscherstr. 74, Dresden, 01307, Germany. martin.kolditz@uniklinikum-dresden.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH